

# Supplementary Materials for

## A proteomics-based analysis reveals predictive biological patterns in Fabry disease

Abdellah Tebani <sup>1</sup>, Wladimir Mauhin <sup>2</sup>, Lenaig Abily-Donval <sup>3,4</sup>, Céline Lesueur <sup>1,4</sup>, Marc G. Berger <sup>5,6</sup>, Yann Nadjar <sup>7</sup>, Juliette Berger <sup>5,6</sup>, Oliver Benveniste <sup>8</sup>, Foudil Lamari <sup>9</sup>, Pascal Laforêt <sup>10</sup>, Esther Noel<sup>11</sup>, Stéphane Marret <sup>3,4</sup>, Olivier Lidove <sup>2</sup>, Soumeiya Bekri <sup>1</sup> and <sup>4\*</sup>

<sup>1</sup> Department of Metabolic Biochemistry, Rouen University Hospital, Rouen, 76000, France

<sup>2</sup> Department of Internal Medicine, Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France & INSERM U 974, 75014 Paris, France

<sup>3</sup> Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, Rouen, 76000, France

<sup>4</sup> Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France

<sup>5</sup> CHU Clermont-Ferrand, Hopital Estaing, CRB-Auvergne, 63003, Clermont-Ferrand, France.

<sup>6</sup> Université Clermont Auvergne, EA 7453 CHELTER, 63000 Clermont-Ferrand

<sup>7</sup> Neurology Department, Reference center for Lysosomal Diseases, Hôpital Pitié-Salpêtrière, Paris, France

<sup>8</sup> Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France & INSERM U 974, 75014 Paris, France

<sup>9</sup> Department of Metabolic Biochemistry, Pitié-Salpêtrière Hospital, APHP-Sorbonne university, Paris, France

<sup>10</sup> Neurology Department, Hôpital Raymond-Poincaré, AP-HP, Garches, France

<sup>11</sup> Department of Internal Medicine, Centre Hospitalier Universitaire, Strasbourg, France.

\* Correspondence: soumeiya.bekri@chu-rouen.fr

### Content


**Figure S1.** Scatter plots and correlation between LysoGb3, residual enzyme activity (REA), FGF2, IL7, VEGFA, and VEGF. Data from treated Fabry samples with classical phenotype. Significant correlations: REA .vs. lysoGb3 (Corr = -0.33, p = 0.04), IL7 .vs. VEGFC (Corr = -0.42, p = 0.01), VEGFA .vs. lysoGb3 (Corr = 0.36, p = 0.04), IL7 .vs. VEGFA (Corr = 0.36, p = 0.04).

**Figure S2.** Scatter plots and correlation between LysoGb3, residual enzyme activity (REA), FGF2, IL7, VEGFA, and VEGF. Data from non-treated Fabry samples with classical phenotype. Significant correlations: REA .vs. lysoGb3 (Corr = -0.41, p = 0.01), FGF2 .vs. VEGFA (Corr = 0.57, p = 0.03).

**Figure S3.** Scatter plots and correlation between LysoGb3, residual enzyme activity (REA), FGF2, IL7, VEGFA, and VEGF. Data from treated Fabry samples with non-classical phenotype. Significant correlations: FGF2 .vs. VEGFC (Corr = 0.42, p = 0.01), FGF2 .vs. IL7 (Corr = 0.10, p = 0.01).


**Figure S4.** Scatter plots and correlation between LysoGb3, residual enzyme activity (REA), FGF2, IL7, VEGFA, and VEGF. Data from non-treated Fabry samples with non-classical phenotype. Significant correlations: IL7 .vs. REA (Corr = -0.76, p = 0.02), FGF2 .vs. IL7 (Corr = 0.42, p = 0.01). corr = Spearman correlation.

### Fabry Classic Phenotype (Treated)




**Figure S1.** Scatter plots and correlation between LysoGb3, residual enzyme activity (REA), FGF2, IL7, VEGFA, and VEGF. Data from treated Fabry samples with classical phenotype. Significant correlations: REA .vs. lysoGb3 (Corr = -0.33, p = 0.04), IL7 .vs. VEGFC (Corr = -0.42, p = 0.01), VEGFA .vs. lysoGb3 (Corr = 0.36, p = 0.04), IL7 .vs. VEGFA (Corr = 0.49, p = 0.2).

### Fabry Classic Phenotype (Non Treated)




**Figure S2.** Scatter plots and correlation between LysoGb3, residual enzyme activity (REA), FGF2, IL7, VEGFA, and VEGF. Data from non-treated Fabry samples with classical phenotype. Significant correlations: REA .vs. lysoGb3 (Corr = -0.41, p = 0.01), FGF2 .vs. VEGFA (Corr = 0.57, p = 0.03).

### Fabry Non Classic Phenotype (Treated)



**Figure S3.** Scatter plots and correlation between LysoGb3, residual enzyme activity (REA), FGF2, IL7, VEGFA, and VEGF. Data from treated Fabry samples with non-classical phenotype. Significant correlations: FGF2 .vs. VEGFC (Corr = 0.43, p = 0.04), FGF2 .vs. IL7 (Corr = 0.42, p = 0.01).

### Fabry Non Classic Phenotype (Non Treated)



**Figure S4.** Scatter plots and correlation between LysoGb3, residual enzyme activity (REA), FGF2, IL7, VEGFA, and VEGF. Data from non-treated Fabry samples with non-classical phenotype. Significant correlations: IL7 .vs. REA (Corr = -0.76, p = 0.02), FGF2 .vs. IL7 (Corr = 0.1, p = 0.01). corr = Spearman correlation. Asterix \* = Significant.